While it is also displayed on many normal hematopoietic cells, the absence of CD38 on the most immature normal blood cells lends itself as a possible target for adoptive cell therapies in AML, a notion indicated by preclinical models showing anti-AML efficacy of anti-CD38 CAR T cells in vitro [107]. This evidence concerns the gene CD38 and acute myeloid leukemia.